Vaxcyte, Inc. (PCVX): Capital Expenditures
$13.71M
Year ended 2025-12-31
$12.90M
Trailing 12 months to 2026-06-30
+32.9%
3-year compound annual growth
+64.0%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $13.71M | -38.9% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $22.43M | +39.6% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $16.06M | +175.0% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $5.84M | -10.9% | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | $6.55M | +467.5% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $1.16M | -3.3% | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $1.20M | -32.6% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $1.77M | n/a | 2021-03-29, From 2018-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Vaxcyte, Inc. (PCVX) | 2025-12-31 | $13.71M | -38.9% |
| Repligen Corp (RGEN) | 2025-12-31 | $23.52M | -8.4% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $8.43M | -70.4% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $28.85M | -7.0% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $6.97M | -34.8% |
| Revolution Medicines, Inc. (RVMD) | 2025-12-31 | $15.99M | +55.1% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $914.0K | -51.9% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $34.00M | -11.0% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $1.45M | -88.7% |
Compare PCVX, RGEN, EXEL, TECH side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗